The brief

Analyst view

• PRISM platform combines RNA editing, splicing, RNAi, and antisense silencing.
• WVE-006 is first clinical ADAR therapy; interim data supports accelerated FDA approval path.
• WVE-007 twice-yearly siRNA for obesity shows durable weight loss while sparing muscle.

Technical approach

As reported

PRISM Platform

Modular RNA targeting

Switch between editing (ADAR, ABEs), splicing, RNAi, and antisense for each target, optimizing mechanism for safety and efficacy.

ADAR Editing

Adenosine-to-inosine conversion

WVE-006 uses ADAR to edit mRNA in place, changing stop codons to sense so cells produce functional protein without gene integration.

GalNAc-siRNA

Liver-targeted infrequent dosing

WVE-007 conjugated siRNA silences INHBE in hepatocytes, reducing visceral fat; chemical liver targeting enables once or twice yearly dosing.